Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer

Jeremy C. Jones, Lindsay A. Renfro, Humaid O. Al-Shamsi, Alexa B. Schrock, Andrew Rankin, Ben Y. Zhang, Pashtoon M. Kasi, Jesse S. Voss, Alexis D. Leal, James Sun, Jeffrey Ross, Siraj M. Ali, Joleen M. Hubbard, Benjamin R. Kipp, Robert R. McWilliams, Scott Kopetz, Robert A. Wolff, Axel Grothey

Research output: Contribution to journalArticlepeer-review

109 Scopus citations

Abstract

Purpose Molecular diagnostic testing has become an integral part of the evaluation of patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next-generation sequencing (NGS), often identifies mutations with unclear clinical or prognostic implications. One such example is BRAF mutations that occur outside of codon 600 (non-V600BRAF mutations). Methods We conducted this multicenter, retrospective cohort study to characterize the clinical, pathologic, and survival implications of non-V600BRAF mutations in metastatic CRC. We pooled patients in whom non-V600BRAF mutations were identified from NGS databases at three large molecular genetics reference laboratories. Results A total of 9,643 patients with metastatic CRC underwent NGS testing. We identified 208 patients with non-V600BRAF mutations, which occurred in 2.2% of all patients tested and accounted for 22% of all BRAF mutations identified. Cancers with non-V600BRAF mutations, compared with cancers with V600E BRAF (V600EBRAF) mutations, were found in patients who were significantly younger (58 v 68 years, respectively), fewer female patients (46% v 65%, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600BRAF-mutant metastatic CRC compared with those with both V600EBRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months, respectively; P <.001). In multivariable analysis, non-V600BRAF mutation was independently associated with improved overall survival (hazard ratio, 0.18; P <.001). Conclusion Non-V600BRAF mutations occur in approximately 2.2% of patients with metastatic CRC and define a clinically distinct subtype of CRC with an excellent prognosis.

Original languageEnglish (US)
Pages (from-to)2624-2630
Number of pages7
JournalJournal of Clinical Oncology
Volume35
Issue number23
DOIs
StatePublished - Aug 10 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '<sup>Non-V600</sup>BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this